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Background: Emerging research seeking novel analgesic drugs focuses on agents targeting group-II metabotropic
glutamate receptors (mGlu2 and mGlu3 receptors). N-Acetylcysteine (NAC) enhances the endogenous activation of
mGlu2/3 receptors by activating the glial glutamate:cystine membrane exchanger. Here, we examined whether NAC
inhibits nociceptive responses in humans and animals. We tested the effect of oral NAC (1.2 g) on thermal-pain
thresholds and laser-evoked potentials in 10 healthy volunteers, according to a crossover, double-blind,
placebo-controlled design, and the effect of NAC (100 mg/kg, i.p.) on the tail-flick response evoked by radiant heat
stimulation in mice.
Results: In healthy subjects, NAC treatment left thermal-pain thresholds unchanged, but significantly reduced
pain ratings to laser stimuli and amplitudes of laser-evoked potentials. NAC induced significantly greater changes
in these measures than placebo. In the tail-flick test, NAC strongly reduced the nocifensive reflex response to radiant
heat. The action of NAC was abolished by the preferential mGlu2/3 receptor antagonist, LY341495 (1 mg/kg, i.p.).
Conclusions: Our findings show for the first time that NAC inhibits nociceptive transmission in humans, and does the
same in mice by activating mGlu2/3 receptors. These data lay the groundwork for investigating the therapeutic
potential of NAC in patients with chronic pain.
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Despite recent advances, only few patients suffering
from chronic pain achieve acceptable pain relief with the
currently available analgesic drugs [1].
Potential targets for novel analgesic drugs include
group-II metabotropic glutamate receptor subtypes
(mGlu2 and mGlu3 receptors) [2,3]. mGlu2 and
mGlu3 receptors localized in the spinal cord and other
regions of the nociceptive system negatively regulate glu-
tamate release by reducing cAMP formation and inhi-
biting voltage-sensitive calcium channels in presynaptic* Correspondence: ferdinandonicoletti@hotmail.com
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unless otherwise stated.terminals [2,4]. Immune gold labelling has shown that
both receptors are preferentially (albeit not exclusively)
localized in the preterminal axonal region, and are there-
fore inaccessible to synaptic glutamate. A growing body of
evidence suggests that presynaptic mGlu2 and mGlu3
receptors are activated by the glutamate released from as-
trocytes via the glutamate:cystine antiporter (Sxc-) [5,6]. A
drug that activates Sxc-, and might therefore be used to
reinforce the endogenous activation of mGlu2/3 receptors,
is N-acetylcysteine (NAC) [7]. We have shown recently
that NAC induces analgesia in animal models of inflam-
matory and neuropathic pain [8]. NAC-induced analgesia
was abolished by genetic deletion of mGlu2 receptors or
by co-treatment with the preferential mGlu2/3 receptor
antagonist, LY341495 [8]. The study of nociceptivehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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towards the clinical research of NAC in patients with
chronic pain.
In this study we examined whether oral NAC was able
to modulate nociceptive transmission in healthy volun-
teers. Using a double-blind, placebo-controlled design,
we tested NAC-induced changes in quantitative sensory
testing and laser-evoked potentials, two techniques that
international guidelines indicate as “reference stan-
dards” for assessing the nociceptive system and testing
analgesic efficacy [9-11]. As an experimental counter-
part in animals, we also examined changes induced by
intraperitoneal-injected NAC on the tail-flick test elic-
ited by radiant heat in mice, the animal model most
closely corresponding to laser stimulation in humans.Figure 1 Oral NAC inhibits nociceptive transmission in healthy
volunteers. A: Laser-evoked potential (LEP) recordings during placebo
and N-acetyl-cysteine (NAC) sessions in a representative subject. Black:
pre-drug recordings. Grey: post-drug recordings. Each trace is the mean
of 20 trials. Horizontal calibration: 100 ms; vertical calibration:
20 μV. B: Mean pre-drug (black) and post-drug (grey) values for N1,
N2-P2 amplitude LEP components and laser pain ratings during
placebo and NAC sessions. Whereas placebo was ineffective, NAC
significantly reduced all LEP components and laser pain ratings.
Values are means + S.E.M. of 10 determinations. *p < 0.02; **p < 0.01.Results
NAC-induced changes in nociceptive transmission in
humans
No subjects reported adverse events after receiving NAC
or placebo. The NAC and placebo sessions yielded com-
parable baseline values for quantitative sensory testing
and laser-evoked potential variables (P > 0.1; Table 1).
Baseline values were within the normal ranges estab-
lished in our laboratory.
Oral NAC (1.2 g) significantly attenuated pain evoked
by laser stimuli, and the N1-and N2P2 laser-evoked
potential amplitudes (laser pain ratings: p < 0.01; N1
component: p < 0.02; N2-P2 complex: p < 0.01) (Figure 1),
but left thermal and pain perceptive thresholds un-
changed. Placebo left all variables unchanged (Table 1).NAC-induced changes in tail-flick latencies in mice
A single injection of NAC (100 mg/kg, i.p.; 30 min be-
fore the test) substantially increased tail-flick latencies as
compared with saline injection in mice (p=0.018)
(Figure 2). Pretreatment for 15 min with the preferential
mGlu2/3 receptor antagonist, LY341495 (1 mg/kg, i.p.),
which was inactive on its own, abolished NAC-induced
analgesia (p=0.017) (Figure 2).Table 1 Effect of oral NAC (1.2 g) and placebo on nociceptive
Placebo NAC
Pre-drug Post-drug P Pre-drug
N1-LEP (μV) 7.1 ± 0.8 8.5 ± 0.6 NS 8.3 ± 1.4
N2P2-LEP (μV) 30.9 ± 2.1 29.3 ± 2.1 NS 35.6 ± 3.7
Laser pain (NRS 0-10) 5.6 ± 0.2 5.5 ± 0.2 NS 6.3 ±0.5
Cold detection threshold (°C) 29.1 ± 0.4 28.7 ± 0.5 NS 28.8 ± 0.4
Warm detection threshold (°C) 34.8 ±0.5 35.9 ± 0.8 NS 34.2 ± 0.2
Cold pain threshold (°C) 13.8 ± 2.4 13.6 ± 2.3 NS 13.4 ± 2.5
Heat pain threshold (°C) 43.5 ± 0.7 43.7 ± 0.7 NS 43.8 ± 1.1
Values are means ± S.E.M.Discussion
Our study, showing that oral NAC reduced laser pain
ratings and laser-evoked potential amplitudes, provides
the previously unavailable evidence that NAC inhibits
nociceptive transmission in healthy humans. These find-
ings in humans received confirmation from the NAC-
induced tail-flick suppression in mice.
Precisely where in the nervous system NAC acts to
induce analgesia in the nociceptive transmission path-
way remains unclear. Although mGlu2/3 receptors lie
at various levels across the nociceptive pathway [4], wetransmission in ten healthy volunteers
Placebo NAC
Post-drug P Changes Pre-Post Changes Pre-Post P
4.8 ± 0.8 <0.02 1.6 ± 0.8 - 3.6 ± 3.8 <0.02
21.8 ± 3.1 <0.01 -1.6 ± 1.9 -13.9 ± 3.9 <0.01
5.3 ± 0.5 <0.01 0.05 ± 0.6 -1.0 ± 0.2 <0.01
28.7 ± 0.6 NS -0.4 ± 0.4 -0.1 ± 0.5 NS
35.0 ± 0.4 NS 1.1 ± 0.8 0.8 ± 0.3 NS
14.8 ± 2.5 NS -0.2 ± 1.7 1.4 ± 1.7 NS
43.7 ± 1.1 NS 0.2 ± 0.5 -0.1 ± 0.5 NS
Figure 2 Acute injection of NAC inhibits radiant heat-induced
nocifensive behavior in mice by activating mGlu2/3 receptors.
Percentage of the maximum possible effect (%MPE) in the four
tail-flick conditions: i) saline followed by saline; (ii) saline followed
by N-acetyl-cysteine (NAC) (100 mg/kg); (iii) LY341495 (1 mg/kg)
followed by saline; and (iv) LY341495 followed by NAC. NAC injection
increased tail-flick latencies. Values are means + S.E.M. of 6–8
determinations. *p < 0.05 vs. all other values, F(3,22)=6.38, p=0.003.
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ter release at the synapse between first-order and
second-order nociceptive neurons in the dorsal horn
[12]. This hypothesis is consistent with our data of
laser-evoked potentials showing that NAC concomi-
tantly reduced the N1 component (generated in the SII
area), and the N2-P2 complex (generated in the insular
and cingulate cortex) [13], which is indicative of a
lower action of the drug within the nociceptive path-
way. The hypothesis that NAC induces its analgesic ef-
fect predominantly in the dorsal horn is also supported
by data of the formalin test in mice. NAC specifically
reduced nocifensive behavior in the second phase of
the formalin test [8], which reflects the development of
nociceptive sensitization in the dorsal horn of the
spinal cord [14].
Whereas NAC reduced the laser pain ratings and
laser-evoked potential amplitudes, it left the thermal-
pain thresholds-assessed by the quantitative sensory
testing-unchanged. This finding is not surprising
because analgesic agents, such as opioids and mono-
aminergic drugs, have more pronounced effects on
high-intensity pain (e.g., laser-evoked pain) than on
thermal-pain thresholds [11,15,16].
Unexpectedly in our study we did not find any placebo
effect on laser-evoked potentials. This finding is not in
line with some studies demonstrating that placebo
affects laser-evoked potentials [17]. There are the follow-
ing potential explanations: (i) in our experiments thesubjects received information on the aim of the study;
(ii) our subjects knew they had the chance to receive
placebo; and (iii) all subjects were well-trained neuro-
physiologists and neurologists of our Department, and
this might have minimized the placebo effect.
As expected in none of our subjects did NAC cause
adverse events. NAC, commonly used as a mucolytic
agent, is an extremely safe drug. The standard dose
(600 mg/day) induces negligible adverse effects [18].
Even when given at high I.V. doses in the treatment of
acetaminophen poisoning, its adverse effects are usually
mild and easily managed [19]. Hence, NAC might be an
ideal and safe adjuvant drug for treating patients with
chronic pain undergoing multiple treatments for pain
and the related comorbidities.
Using a radiant heat experimental pain model–similar
to that used in humans–our experiments showed that
tail-flick responses had a longer latency in NAC-treated
mice than in saline-treated mice. The tail-flick delay was
sensitive to the LY341495-induced mGlu2/3 receptor
block. These findings are consistent with the analgesic
effect of NAC reported in other experimental pain
models (e.g. the formalin test, the complete Freund’s ad-
juvant chronic inflammatory pain model, and in the
chronic constriction injury neuropathic pain model) [8],
and show that mGlu2/3 receptors mediate the NAC-
induced changes in nociceptive transmission in mice.
Conclusions
Our study, showing that NAC reduces laser-induced
pain and laser-evoked brain potentials in humans and
delays the tail-flick response in mice indicates that NAC
inhibits nociceptive transmission. Accordingly, a previ-
ous study directly addressing the efficacy of NAC in
patients with complex regional pain syndrome type I,
has raised the possibility that NAC might be potentially
useful for relieving pain [20]. Hence, because NAC is a
safe drug, it deserves to be tested in further adequately
sized clinical trials in patients with pain.
Methods
Human experiments
Ten healthy volunteers (4 M, 6 F; 23–38 years) partici-
pated in the study. The Institutional Review Board
approved all procedures and all subjects gave their
written informed consent.
The Institutional Review Board of the Policlinico
Umberto I – Department of Neurology and Psychiatry,
Sapienza University approved all procedures and all sub-
jects gave their written informed consent.
Quantitative sensory testing of thermal-pain sensitivity
For quantitative sensory testing we used a thermode
(ATS, PATHWAY, Medoc, Israel). The computer-driven
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tact area 30 × 30 mm) equipped with an external Peltier
element that cools and heats the plate to target levels.
The baseline temperature of 32°C reached target
temperature at a ramp rate of 1°C/s. Quantitative sen-
sory variables were tested on the right hand dorsum. We
tested subjects’ thermal-pain perceptive thresholds: cold
detection threshold (CDT), warm detection threshold
(WDT), cold pain threshold (CPT) and heat pain thresh-
old (HPT).Laser-evoked potentials
We used a Nd: YAP laser stimulator under fiber–optic
guidance (Electronic Engineering, Florence, Italy). Laser
stimuli were set to induce a clear painful pinprick (inten-
sity 119.4-150 mJ/mm2; duration 5 ms; diameter 4 mm)
and directed to the right hand dorsum. The laser beam
was shifted after each stimulus and the interstimulus
interval was varied pseudo-randomly (10–15 s). Subjects,
wearing protective goggles, rested comfortably on a
medical examination table, keeping their eyes open. The
different laser evoked potential components were re-
corded through disk electrodes from the scalp: T3 refer-
enced to Fz for recording the early lateralized N1
component, and Cz referenced to the nose, for recording
the late vertex N2-P2 complex. Electro-oculographic re-
cordings monitored possible eye movements or blinks.
For each session, two series of 10–15 artefact-free trials
were averaged off line. We measured the peak latencies
and amplitudes of the lateralized N1 and the vertex N2-
P2 complex. These methods adhered to the recommen-
dations given by the International Federation of Clinical
Neurophysiology [21]. In all sessions the subjects were
asked to rate the pain evoked by laser stimuli on a 0–10
numeric rating scale (NRS) (0=no sensation, 10=worst
possible pain).Experimental procedure
We conducted a double-blind, placebo-controlled, cross-
over study. All subjects underwent two separate sessions,
one with oral N-acetylcysteine (NAC) (effervescent tab-
lets, Ratiopharm, 1.2 g) and the other with oral placebo
(Multicentrum, multivitamin supplement, in effervescent
tablets). The two sessions were randomly alternated
among subjects. Two investigators, both unaware of the
type of session (drug or placebo), recorded the thermal-
pain perceptive thresholds and laser evoked potential
measures. Each session comprised two recording blocks:
before oral NAC or placebo (pre-drug), and 60 min after
NAC or placebo (post-drug). As primary outcome vari-
ables, we selected the warm and cold detection thresh-
olds, the cold and heat pain thresholds; N1 component
and N2-P2 laser-evoked potential amplitudes and thenumerical rating scale for the perceived pain intensity
during the laser evoked potential recordings.
Animal experiments
All experiments were conducted according to the
European (86/609/EEC) and Italian (D: Lgs. 116/92)
guidelines for animal care. The experimental protocol
was approved by the Italian Ministry of Health. All
efforts were made to minimize animal suffering and
the number of animals used.
Drugs
NAC was purchased from Sigma Aldrich (Milano,
Italy). (2S)-2-Amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-
3-(xanth-9-yl) propanoic acid (LY341495) was purchased
from Tocris Cookson (Avonmouth, Bristol, UK).
Tail-flick test
We used adult male C57BL/6 J mice (body weight 25–
28 g) purchased from Charles River (Calco, Italy). All
mice were housed 5 per cage, under a standard 12/12 h
light/dark cycle with food and water ad libitum. Testing
took place from 9:00 a.m. to 11 a.m. on two consecutive
days. Four groups of 6–8 mice received two intraperito-
neal (i.p.) injections separated by a 15-min interval, as
follows: (i) saline followed by saline; (ii) saline followed
by NAC (100 mg/kg); (iii) LY341495 (1 mg/kg) followed
by saline; and (iv) LY341495 followed by NAC. In the
tail-flick test, mice were loosely wrapped in a velvet
towel and placed on the tail-flick apparatus (Tail Flick
model DS 20 Socrel Apelex, France). A light beam was
focused on the tail approximately 1 to 3 cm from the
base, and to minimize tissue damage the latency to a vig-
orous radiant-heat-induced tail flick was measured with
a 10-second cut-off time. Tail-flick latencies at baseline
(BL) were measured 3 times per mouse at 2-min inter-
vals, and 5 min before the first i.p. injection. The study
included only mice whose mean baseline reaction times
ranged between 3 and 5 sec. Latencies were measured
again 30 min after the second i.p. injection (test
latency, TL). Results were expressed as a percentage of
the maximum possible effect (%MPE) using the follow-
ing formula: %MPE=100_{(TL–mean BL)/(Cut-off
time–mean BL)}.
Statistical analysis
Because several variables for human subjects had a non-
normal distribution, all comparisons in humans were
analyzed for significance with the Wilcoxon signed-rank
test. Data for tail-flick in mice were tested with a one-
way analysis of variance (ANOVA) followed by Dunnett’s
t test to isolate the differences. P values <0.05 were
considered as statistically significant.
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